摘要

Vascular endothelial growth factor (VEGF) inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), are important as anticancer treatments through curbing tumour angiogenesis and growth. VEGF inhibitors have significant cardiovascular effects. By blocking VEGF receptors, ligands, or signal pathways, VEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity, and activate cardiomyocyte apoptosis. VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia. Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors. This review updates current understandings of VEGF inhibitors on cardiovascular toxicity, explores potential mechanisms, and clarifies whether genetic or ethnic factors contribute to their adverse effects.Key MessagesVEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity and activate cardiomyocyte apoptosis.VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia.Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors.
原文英語
頁(從 - 到)46-56
頁數11
期刊Annals of Medicine
50
發行號1
DOIs
出版狀態已發佈 - 一月 2 2018

指紋

Vascular Endothelial Growth Factor A
Thromboembolism
Genetic Polymorphisms
Vasoconstriction
Cardiac Myocytes
Vasodilation
Cardiac Arrhythmias
Endothelial Cells
Heart Failure
Apoptosis
Hypertension
Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Signal Transduction
Monoclonal Antibodies
Ligands
Growth
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

引用此文

@article{0732434a67ad423faaea969a1419d9ed,
title = "Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors",
abstract = "Vascular endothelial growth factor (VEGF) inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), are important as anticancer treatments through curbing tumour angiogenesis and growth. VEGF inhibitors have significant cardiovascular effects. By blocking VEGF receptors, ligands, or signal pathways, VEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity, and activate cardiomyocyte apoptosis. VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia. Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors. This review updates current understandings of VEGF inhibitors on cardiovascular toxicity, explores potential mechanisms, and clarifies whether genetic or ethnic factors contribute to their adverse effects.Key MessagesVEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity and activate cardiomyocyte apoptosis.VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia.Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors.",
keywords = "Angiogenesis inhibitors, antibodies, cardiotoxicity, cardiovascular system, ethnic groups, tyrosine kinase inhibitors, vascular endothelial growth factors",
author = "Chen, {Yen Chou} and Chung, {Cheng Chih} and Lin, {Yung Kuo} and Chen, {Yi Jen}",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/07853890.2017.1383629",
language = "English",
volume = "50",
pages = "46--56",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors

AU - Chen, Yen Chou

AU - Chung, Cheng Chih

AU - Lin, Yung Kuo

AU - Chen, Yi Jen

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Vascular endothelial growth factor (VEGF) inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), are important as anticancer treatments through curbing tumour angiogenesis and growth. VEGF inhibitors have significant cardiovascular effects. By blocking VEGF receptors, ligands, or signal pathways, VEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity, and activate cardiomyocyte apoptosis. VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia. Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors. This review updates current understandings of VEGF inhibitors on cardiovascular toxicity, explores potential mechanisms, and clarifies whether genetic or ethnic factors contribute to their adverse effects.Key MessagesVEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity and activate cardiomyocyte apoptosis.VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia.Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors.

AB - Vascular endothelial growth factor (VEGF) inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs), are important as anticancer treatments through curbing tumour angiogenesis and growth. VEGF inhibitors have significant cardiovascular effects. By blocking VEGF receptors, ligands, or signal pathways, VEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity, and activate cardiomyocyte apoptosis. VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia. Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors. This review updates current understandings of VEGF inhibitors on cardiovascular toxicity, explores potential mechanisms, and clarifies whether genetic or ethnic factors contribute to their adverse effects.Key MessagesVEGF inhibitors disturb the balance between vasodilation and vasoconstriction, undermine endothelial cell integrity and activate cardiomyocyte apoptosis.VEGF inhibitors increase risks of hypertension, heart failure, thromboembolism and arrhythmia.Genetic and geographic studies showed that genetic polymorphisms likely play significant predictive or prognostic roles in cardiovascular toxicity associated with VEGF inhibitors.

KW - Angiogenesis inhibitors

KW - antibodies

KW - cardiotoxicity

KW - cardiovascular system

KW - ethnic groups

KW - tyrosine kinase inhibitors

KW - vascular endothelial growth factors

UR - http://www.scopus.com/inward/record.url?scp=85030173422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030173422&partnerID=8YFLogxK

U2 - 10.1080/07853890.2017.1383629

DO - 10.1080/07853890.2017.1383629

M3 - Article

VL - 50

SP - 46

EP - 56

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 1

ER -